Is Illumina Still a Good Stock to Buy?

83
28
Favorite

Is Illumina Still a Good Stock to Buy?

Motley Fool 2021-04-05

The company's attempts to grow through acquisition keep running into problems. The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（28）

Lim89
·2021-04-06
Yes
Reply
Like
Report
Wallstrtbets
·2021-04-06
Yes, good bye.
Reply
1
Report
ISSEY1413
·2021-04-06
Likes and comments appreciated. Thank you!
Reply
1
Report
EstherPang
·2021-04-06
Yes
Reply
1
Report
Glenna
·2021-04-06
pls comment
Reply
1
Report
Roarhigher
·2021-04-06
Buy
Reply
1
Report
Jaaaaaaa
·2021-04-06
Bump
Reply
Like
Report
BpchuA
·2021-04-06
Amazing
Reply
Like
Report
SLabcd
·2021-04-06
I watch Continue down than early quarter of feb
Reply
1
Report
Fold Replies
- Jianhaolee:
  good
  2021-04-06
  Reply
  Report
1nu
·2021-04-06
help me like and comment :)
Reply
Like
Report
Fold Replies
- Jianhaolee:
  nice
  2021-04-06
  Reply
  Report
Cumcumber
·2021-04-06
What they do?
Reply
1
Report
Fold Replies
- Cumcumber:
  ??
  2021-04-12
  Reply
  Report
- mQ:
  Was it good earlier?
  2021-04-09
  Reply
  Report
CherryPang
·2021-04-06
No so good
Reply
1
Report
w8w8
·2021-04-06
Steamed
Reply
1
Report
Fold Replies
- Fredwkh:
  Haha
  2021-04-06
  Reply
  Report
1nquisit0
·2021-04-06
no
Reply
1
Report
dontlose
·2021-04-06
No
Reply
1
Report
Karlok
·2021-04-05
Nice
Reply
1
Report
Fold Replies
- Vivienrose:
  [财迷][财迷]
  2021-04-06
  Reply
  Report
3piglet
·2021-04-05
No hold
Reply
Like
Report
VivalaRan
·2021-04-05
Hmmmm
Reply
2
Report
bbwwdd
·2021-04-05
Buy it
Reply
2
Report
Fold Replies
- xxbbew:
  buy
  2021-04-05
  Reply
  Report
SK29
·2021-04-05
Good
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2125765056?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-05 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2125765056","market":"us","top_or_hot":-1,"title":"Is Illumina Still a Good Stock to Buy?","media":"Motley Fool ","content":"<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","article_id":"2125765056","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","pubTimestamp":1617633583,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The company's attempts to grow through acquisition keep running into problems.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"Illumina是否仍是一支值得购买的好股票？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":0.9},"content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":343044959,"gmtCreate":1617666533871,"gmtModify":1704701470498,"author":{"id":"3527303552443900","authorId":"3527303552443900","name":"Lim89","avatar":"https://static.tigerbbs.com/f21e4020ff962f4d66f99662b584ec1c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3527303552443900","authorIdStr":"3527303552443900"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343044959","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":343048616,"gmtCreate":1617666392935,"gmtModify":1704701465153,"author":{"id":"3566244878628904","authorId":"3566244878628904","name":"Wallstrtbets","avatar":"https://static.tigerbbs.com/6c38bbee1121ea92508ad9508fa15c5e","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3566244878628904","authorIdStr":"3566244878628904"},"htmlText":"Yes, good bye.","listText":"Yes, good bye.","text":"Yes, good bye.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343048616","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":343028256,"gmtCreate":1617664993975,"gmtModify":1704701437236,"author":{"id":"3580024367177542","authorId":"3580024367177542","name":"ISSEY1413","avatar":"https://static.tigerbbs.com/3aae359514ad4455bfc28cf62f608a5e","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":6,"crmLevelSwitch":1,"idStr":"3580024367177542","authorIdStr":"3580024367177542"},"htmlText":"Likes and comments appreciated. Thank you!&nbsp;","listText":"Likes and comments appreciated. Thank you!&nbsp;","text":"Likes and comments appreciated. Thank you!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343028256","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":343021724,"gmtCreate":1617664966368,"gmtModify":1704701436103,"author":{"id":"3576365817943823","authorId":"3576365817943823","name":"EstherPang","avatar":"https://static.tigerbbs.com/8990239e19377757a2b24cf2333a310d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576365817943823","authorIdStr":"3576365817943823"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343021724","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":343064057,"gmtCreate":1617664503779,"gmtModify":1704701428663,"author":{"id":"3570769377369254","authorId":"3570769377369254","name":"Glenna","avatar":"https://static.tigerbbs.com/8cb1540811be40c4d05341502c35498c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570769377369254","authorIdStr":"3570769377369254"},"htmlText":"pls comment&nbsp;","listText":"pls comment&nbsp;","text":"pls comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343064057","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":343061966,"gmtCreate":1617664042055,"gmtModify":1704701422153,"author":{"id":"3555104076236141","authorId":"3555104076236141","name":"Roarhigher","avatar":"https://static.tigerbbs.com/80741e96f295312c1997c6a41bb6ea13","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3555104076236141","authorIdStr":"3555104076236141"},"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343061966","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":343087997,"gmtCreate":1617663713519,"gmtModify":1704701417781,"author":{"id":"3570001951488746","authorId":"3570001951488746","name":"Jaaaaaaa","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570001951488746","authorIdStr":"3570001951488746"},"htmlText":"Bump","listText":"Bump","text":"Bump","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343087997","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":343082777,"gmtCreate":1617663503599,"gmtModify":1704701414227,"author":{"id":"3575867013914101","authorId":"3575867013914101","name":"BpchuA","avatar":"https://static.tigerbbs.com/dd3500e66cc249b4480fcc30d7cd6409","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3575867013914101","authorIdStr":"3575867013914101"},"htmlText":"Amazing","listText":"Amazing","text":"Amazing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343082777","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":343080833,"gmtCreate":1617662804522,"gmtModify":1704701406945,"author":{"id":"3561687131790412","authorId":"3561687131790412","name":"SLabcd","avatar":"https://static.tigerbbs.com/ee729bc8a6e8b42e7c9da20e9bbab6b8","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3561687131790412","authorIdStr":"3561687131790412"},"htmlText":"I watch&nbsp;Continue down than early quarter of feb","listText":"I watch&nbsp;Continue down than early quarter of feb","text":"I watch Continue down than early quarter of feb","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/343080833","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3965673,"gmtCreate":1617663322058,"gmtModify":1680782981316,"authorId":3567803092148771,"author":{"id":3567803092148771,"idStr":"3567803092148771","authorId":3567803092148771,"name":"Jianhaolee","avatar":"https://static.tigerbbs.com/aa1f86bdb9ab104312dbfcceafe99e40","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":343080833,"type":1,"supId":0,"prevId":0,"content":"good","text":"good","html":"good"}],"langContent":"EN"},{"id":343015576,"gmtCreate":1617662509195,"gmtModify":1704701403526,"author":{"id":"3577610430427001","authorId":"3577610430427001","name":"1nu","avatar":"https://static.tigerbbs.com/15789a74f3eb14371af59c44a8f71041","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577610430427001","authorIdStr":"3577610430427001"},"htmlText":"help me like and comment :)","listText":"help me like and comment :)","text":"help me like and comment :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/343015576","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3965675,"gmtCreate":1617663329791,"gmtModify":1680782984150,"authorId":3567803092148771,"author":{"id":3567803092148771,"idStr":"3567803092148771","authorId":3567803092148771,"name":"Jianhaolee","avatar":"https://static.tigerbbs.com/aa1f86bdb9ab104312dbfcceafe99e40","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":343015576,"type":1,"supId":0,"prevId":0,"content":"nice","text":"nice","html":"nice"}],"langContent":"EN"},{"id":343016597,"gmtCreate":1617662273619,"gmtModify":1704701400921,"author":{"id":"3575627435539854","authorId":"3575627435539854","name":"Cumcumber","avatar":"https://static.tigerbbs.com/1e62601ef19050a454d9e0097dbba348","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"3575627435539854","authorIdStr":"3575627435539854"},"htmlText":"What they do?","listText":"What they do?","text":"What they do?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/343016597","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4010460,"gmtCreate":1618184038649,"gmtModify":1680783672772,"authorId":3575627435539854,"author":{"id":3575627435539854,"idStr":"3575627435539854","authorId":3575627435539854,"name":"Cumcumber","avatar":"https://static.tigerbbs.com/1e62601ef19050a454d9e0097dbba348","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.03","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":343016597,"type":1,"supId":3990188,"prevId":0,"content":"??","text":"??","html":"??"},{"id":3990188,"gmtCreate":1617921009170,"gmtModify":1680783354808,"authorId":3575883708634905,"author":{"id":3575883708634905,"idStr":"3575883708634905","authorId":3575883708634905,"name":"mQ","avatar":"https://static.tigerbbs.com/f15c6544cce801bf2702a439bc97d760","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":343016597,"type":1,"supId":0,"prevId":0,"content":"Was it good earlier?","text":"Was it good earlier?","html":"Was it good earlier?"}],"langContent":"EN"},{"id":343010760,"gmtCreate":1617661861750,"gmtModify":1704701394242,"author":{"id":"3579242284896142","authorId":"3579242284896142","name":"CherryPang","avatar":"https://static.tigerbbs.com/72256d5f02e9431fb7df955e5b3418f8","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"3579242284896142","authorIdStr":"3579242284896142"},"htmlText":"No so good","listText":"No so good","text":"No so good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343010760","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":343098692,"gmtCreate":1617659762616,"gmtModify":1704701372439,"author":{"id":"3575859183800572","authorId":"3575859183800572","name":"w8w8","avatar":"https://static.tigerbbs.com/1a305fe39d1c227693a64cc331afda1a","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3575859183800572","authorIdStr":"3575859183800572"},"htmlText":"Steamed","listText":"Steamed","text":"Steamed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/343098692","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3965452,"gmtCreate":1617661585073,"gmtModify":1680782983598,"authorId":3570424148942091,"author":{"id":3570424148942091,"idStr":"3570424148942091","authorId":3570424148942091,"name":"Fredwkh","avatar":"https://static.tigerbbs.com/301d103aff8ff9955978aa630ee85588","vip":1,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":343098692,"type":1,"supId":0,"prevId":0,"content":"Haha","text":"Haha","html":"Haha"}],"langContent":"EN"},{"id":343004326,"gmtCreate":1617658542065,"gmtModify":1704701363186,"author":{"id":"3553900041025922","authorId":"3553900041025922","name":"1nquisit0","avatar":"https://static.tigerbbs.com/3c22511f65f9157a35a7f105f2b1d9bf","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3553900041025922","authorIdStr":"3553900041025922"},"htmlText":"no","listText":"no","text":"no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343004326","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":349729107,"gmtCreate":1617640393609,"gmtModify":1704701305005,"author":{"id":"3578390540207500","authorId":"3578390540207500","name":"dontlose","avatar":"https://static.tigerbbs.com/83dae59fdfe891a662b9f6cf00aeefbb","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3578390540207500","authorIdStr":"3578390540207500"},"htmlText":"No","listText":"No","text":"No","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349729107","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":349795178,"gmtCreate":1617636301394,"gmtModify":1704701247140,"author":{"id":"3575076380849834","authorId":"3575076380849834","name":"Karlok","avatar":"https://static.tigerbbs.com/0f1696696cc5642431fc179f63d9df7a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575076380849834","authorIdStr":"3575076380849834"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/349795178","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3965112,"gmtCreate":1617653284397,"gmtModify":1680782974563,"authorId":3575585519231161,"author":{"id":3575585519231161,"idStr":"3575585519231161","authorId":3575585519231161,"name":"Vivienrose","avatar":"https://static.tigerbbs.com/def4c9c09d2d61a66e1bd9447e42aa29","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349795178,"type":1,"supId":0,"prevId":0,"content":"[财迷][财迷]","text":"[财迷][财迷]","html":"[财迷][财迷]"}],"langContent":"EN"},{"id":349702711,"gmtCreate":1617635611833,"gmtModify":1704701233871,"author":{"id":"3573385929982547","authorId":"3573385929982547","name":"3piglet","avatar":"https://static.tigerbbs.com/6d75c13e0fb682bf1746d89879850b9e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573385929982547","authorIdStr":"3573385929982547"},"htmlText":"No hold","listText":"No hold","text":"No hold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349702711","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":349701674,"gmtCreate":1617635505598,"gmtModify":1704701228673,"author":{"id":"3573442142945386","authorId":"3573442142945386","name":"VivalaRan","avatar":"https://static.tigerbbs.com/bbdf1f2a57583bc2d6a9cae2d7c9b451","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573442142945386","authorIdStr":"3573442142945386"},"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349701674","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":349475871,"gmtCreate":1617635147493,"gmtModify":1704701220581,"author":{"id":"3573877626682233","authorId":"3573877626682233","name":"bbwwdd","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573877626682233","authorIdStr":"3573877626682233"},"htmlText":"Buy it","listText":"Buy it","text":"Buy it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/349475871","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3964215,"gmtCreate":1617635214753,"gmtModify":1680782957613,"authorId":3573467106982618,"author":{"id":3573467106982618,"idStr":"3573467106982618","authorId":3573467106982618,"name":"xxbbew","avatar":"https://static.tigerbbs.com/39068f2ebe66e4e0b64c90ad557577c0","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349475871,"type":1,"supId":0,"prevId":0,"content":"buy","text":"buy","html":"buy"}],"langContent":"EN"},{"id":349447527,"gmtCreate":1617634730569,"gmtModify":1704701210053,"author":{"id":"3564828470827775","authorId":"3564828470827775","name":"SK29","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3564828470827775","authorIdStr":"3564828470827775"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349447527","repostId":2125765056,"repostType":4,"repost":{"id":"2125765056","kind":"highlight","pubTimestamp":1617633583,"share":"https://ttm.financial/m/news/2125765056?lang=&edition=fundamental","pubTime":"2021-04-05 22:39","market":"us","language":"en","title":"Is Illumina Still a Good Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2125765056","media":"Motley Fool ","summary":"The company's attempts to grow through acquisition keep running into problems.","content":"<p>The company's attempts to grow through acquisition keep running into problems.</p>\n<p>The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from&nbsp;<b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a></b> (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.</p>\n<p>If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4aed7ea7abcf78d8c092d9000de55cb\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p><b>A tougher antitrust case to argue</b></p>\n<p>In December 2019, the FTC argued against Illumina's proposed acquisition of&nbsp;<b>Pacific Biosciences</b> (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.</p>\n<p>Illumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.</p>\n<p>Illumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.</p>\n<p><b>Innovation diminisher?</b></p>\n<p>Instead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.</p>\n<p>Blocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.</p>\n<p>The FDA has approved tumor profiling tests from&nbsp;<b>Roche</b> (OTC:RHHBY) and&nbsp;<b>Guardant Health</b> (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.</p>\n<p><b>Likely scenario</b></p>\n<p>Antitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.</p>\n<p>GRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.</p>\n<p>Since there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.</p>\n<p><b>A winner either way</b></p>\n<p>The FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.</p>\n<p>Illumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Illumina Still a Good Stock to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Illumina Still a Good Stock to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/><strong>Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ILMN":"Illumina"},"source_url":"https://www.fool.com/investing/2021/04/05/is-illumina-still-a-good-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125765056","content_text":"The company's attempts to grow through acquisition keep running into problems.\nThe world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ:ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.\nIf the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.\nImage source: Getty Images.\nA tougher antitrust case to argue\nIn December 2019, the FTC argued against Illumina's proposed acquisition of Pacific Biosciences (NASDAQ:PACB) for $1.2 billion. PacBio is a much smaller manufacturer of next-generation DNA sequencing technology, which made it fairly easy to argue that Illumina was trying to extinguish a competitive threat.\nIllumina terminated its merger agreement with PacBio a few weeks after the FTC challenged the buyout, but the company won't give in as quickly this time around. Now, the FTC is trying to stop Illumina from buying GRAIL, a company Illumina initially founded to develop blood-based tests for early cancer detection.\nIllumina spun GRAIL off into a separate business in 2017 and still owns 14.5% of the privately held company. As an aspiring multicancer early detection (MCED) provider, GRAIL doesn't manufacture DNA sequencing machines. GRAIL simply relies on them to run samples drawn from patients. That means the FTC can't allege monopoly-seeking and instead has to rely on the courts to establish a new reason to prohibit mergers.\nInnovation diminisher?\nInstead of a simple monopoly-seeking case, the FTC proposes to stifle this merger on the grounds that it would diminish innovation in the U.S. market for MCED tests. That's because Illumina is effectively the only provider of DNA sequencing for GRAIL and its potential competitors.\nBlocking a merger because it could choke off a critical input for all MCED test providers is an argument that might hold up if the FTC had evidence to that effect. However, this case is going to be extremely difficult for the agency to argue, because MCEDs are still in a prelaunch phase.\nThe FDA has approved tumor profiling tests from Roche (OTC:RHHBY) and Guardant Health (NASDAQ:GH) for people already diagnosed with cancer. These tests can tell oncologists which genetic mutations are driving a patient's disease from a vial of blood. However, the FDA hasn't approved any MCEDs from GRAIL or its potential competitors.\nLikely scenario\nAntitrust regulators wouldn't have a problem here if Illumina had retained ownership of GRAIL in 2017, but the company isn't interested in starting from scratch. Illumina is likely to forge ahead with its planned acquisition of GRAIL to keep pace with Roche and Guardant Health.\nGRAIL should be ready to launch its MCED test as a laboratory-developed test this year. But that isn't the same as an FDA approval that would make it a lot easier for GRAIL to bill insurers and Medicare for its services.\nSince there isn't an MCED industry as such yet, and laws already exist to prevent Illumina from treating potential competitors unfairly, it's hard to see how the FTC's lawsuit could go very far. But if a court rules against Illumina, the ruling could affect any successful service provider that tries to buy a business it services.\nA winner either way\nThe FTC's lawsuit is hardly a reason to avoid the stock. After all, the commission's complaint stems from the fact that Illumina dominates the market for next-generation DNA sequencing.\nIllumina thinks the market for clinical diagnostics that rely on next-generation DNA sequencing will reach $75 billion by 2035. As the lead provider of picks and shovels for this gold rush, Illumina shares still have what it takes to outperform.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":83,"commentSize":28,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}